Monoclonal antibodies · immunohistochemistry

Monoclonal antibodies for immunohistochemistry.

Validated antibodies for IHC on human FFPE tissue — with a full datasheet and published study data for each clone.

Anti-TRPS1 (VB2A2) IHC staining in human breast carcinoma
Anti-TRPS1 (VB2A2) · human breast carcinomaclick to zoom
Catalog

Find an antibody

Search by target protein or clone ID. Full datasheet, representative micrographs, and published performance data for each clone.

Background

About TRPS1

TRPS1 (trichorhinophalangeal syndrome type 1) is a GATA-family zinc-finger transcription factor that has emerged as a sensitive immunohistochemical marker of breast origin. It is expressed across all molecular subtypes of breast carcinoma and shows particularly high sensitivity in triple-negative and basal-like disease, where it can exceed the sensitivity of the established marker GATA3. In diagnostic practice, TRPS1 IHC is used to help confirm or exclude a breast primary when evaluating metastatic carcinoma of uncertain origin.

TRPS1 staining is nuclear. As with any single marker, specificity is not absolute — a subset of non-breast tumors, particularly high-grade gynecologic carcinomas, can show TRPS1 positivity — so it is best interpreted as part of an antibody panel and in morphologic context. Anti-TRPS1 clone VB2A2 is a rabbit monoclonal antibody for IHC on formalin-fixed, paraffin-embedded human tissue; its performance in breast and gynecologic tumors has been characterized in the published studies below.

Published data

Independent literature

Peer-reviewed and meeting-presented studies on TRPS1 immunohistochemistry, including head-to-head clone comparisons. Full text is available from the original publisher.

A Comparison of Three TRPS1 Antibodies in Detecting TRPS1 Expression in Breast Carcinoma and Ovarian Serous Carcinoma
Sun H, Zheng L, Huang X, Han C, Liu J, Wu Y, Ding Q — MD Anderson Cancer Center; UT Southwestern; University of Alabama at Birmingham
Laboratory Investigation 105 (2025) 102980 · USCAP 2025, abstract 748
A 518-case study comparing three commercial TRPS1 antibody clones — including VB2A2 — across breast carcinoma and ovarian serous carcinoma. See the publication for the full comparison and results.
Updates on utility of immunohistochemistry in diagnosis of metastatic breast cancer
Sun H, Sahin AA, Ding Q — Department of Pathology, The University of Texas M.D. Anderson Cancer Center, Houston, TX
Human Pathology 2025 Aug;162:105821 · PMID 40441446 · DOI 10.1016/j.humpath.2025.105821
A review of traditional and newly identified breast markers — with a focus on TRPS1 — for confirming or excluding a breast origin in metastatic carcinoma, and the challenges of distinguishing metastatic breast cancer from malignancies of other origins.
Contact

Get in touch

For product information, datasheets, or supply inquiries, send a note using the form and we'll reply directly.